Complete Response With Cetuximab-Based Treatment of Metastatic Colorectal Cancers: Two Case Reports and Literature Review

Frontiers in Oncology

Li Wei¹  Tiantian Wang¹  Zexiao Lin¹  Zhanhong Chen¹  Qu Lin¹  Danyun Ruan¹  Sidong Xie²  Yueli Cui³  Sisi Liu³  Wen Jiang³ 

[1] Department of Oncology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China;Department of Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China;Department of Research and Development, Nanjing Geneseeq Technology Inc., Nanjing, China;

关键词: cetuximab;    colorectal cancer;    liver metastasis;    targeted therapy;    complete response;   

DOI  :  10.3389/fonc.2022.798515

来源: DOAJ

【 摘 要 】

Metastases typically develop before diagnosis and during the treatment of colorectal cancers, while patients with metastatic colorectal cancers (mCRCs) currently have a poor prognosis. In terms of surgical approaches, adjuvant therapies, and targeted therapies, the treatment of mCRCs has had numerous recent advances. As a targeted agent widely used in mCRCs, cetuximab-based treatment is still under dispute due to its side effects and unstable effect. We present two mCRC cases treated with cetuximab-based therapy, of which two patients achieved complete response and without recurrence for over 22 and 84 months, respectively. To better understand the drug usage, we also reviewed the recent achievements and usage precautions of cetuximab in mCRCs. Present and many previous observations support that cetuximab might be a referred drug in the first-line chemotherapy of mCRCs with wild-type RAS and BRAF and proficient mismatch repair.

【 授权许可】

Unknown